论文部分内容阅读
目的探讨不同疗程的重组人干扰素(IFN)α-2b(安福隆)治疗乙型肝炎病毒e抗原(HBeAg)阳性慢性乙型肝炎(CHB)的疗效并比较随访12个月的结果。方法 72例CHB患者,其中男性46例,女性26例;年龄16~50岁,平均年龄32岁。病程1.8~27.0年,平均病程13.0年。随机分2组,Ⅰ组(42例)予重组人IFNα-2b5MU,肌内注射,开始2周1次/天,2周后改为1次/2天,疗程12个月。Ⅱ组(30例)方法同上,疗程6个月。结果丙氨酸氨基转移酶(ALT)复常率两组病例治疗结束、随访6个月时差异无统计学意义(P>0.05),随访12个月时,Ⅰ组复常率高于Ⅱ组(P<0.05)。HBeAg阴转率及HBeAg/抗乙型肝炎病毒e抗体(HBe)血清学转换率:Ⅰ组病例在治疗结束、随访6个月及12个月时均比Ⅱ组病例高(P<0.05);HBV DNA转阴率:Ⅰ组病例治疗结束时、随访6个月及12个月时均比Ⅱ组病例高(P<0.05)。结论长疗程(12个月)组疗效比短疗程(6个月)组的疗效好,持续和维持应答率高,HBeAg阳性CHB应用重组人IFNα-2b时疗程以12个月为宜。
Objective To investigate the curative effect of different courses of interferon α-2b (An Fulong) on hepatitis B virus e antigen (HBeAg) -positive chronic hepatitis B (CHB) and to compare the results of follow-up 12 months. Methods 72 cases of CHB patients, including 46 males and 26 females; aged 16 to 50 years, mean age 32 years. Duration of 1.8 ~ 27.0 years, the average duration of 13.0 years. Randomly divided into two groups, Ⅰ group (42 cases) to recombinant human IFNα-2b5MU, intramuscular injection, 2 weeks start 1 / day, 2 weeks later changed to 1/2 days for 12 months. Group Ⅱ (30 cases) method above, the course of 6 months. Results The normalization rate of alanine aminotransferase (ALT) was no significant difference between the two groups at 6 months follow-up (P> 0.05). At the 12-month follow-up, the recovery rate of group A was higher than that of group Ⅱ (P <0.05). HBeAg seroconversion rate and HBeAg / HBe seroconversion rate: The patients in group Ⅰ were higher than those in group Ⅱ at the end of treatment and at the follow - up of 6 months and 12 months (P <0.05); HBV DNA negative rate: At the end of treatment, the patients in group Ⅰ were higher than those in group Ⅱ at 6 months and 12 months of follow-up (P <0.05). Conclusion The efficacy of long-term treatment (12 months) is better than that of short-term treatment (6 months), and the sustained and sustained response rate is high. The treatment of HBeAg-positive CHB with recombinant human IFNα-2b is suitable for 12 months.